Crispr Therapeutics awarded grant from FARA
CRISPR Therapeutics announced the receipt of the Kyle Bryant Translational Research Award from Friedreich's Ataxia Research Alliance, or FARA, a non-profit organization that is focused on curing Friedreich's Ataxia, or FA. The grant is awarded to fund research on in vivo CRISPR/Cas9-based gene-editing approaches to treat FA, which will be performed in collaboration with Dr. Marek Napierala at University of Alabama at Birmingham. This announcement coincides with FARA's rideATAXIA Philadelphia event, a lead location in an annual bike ride program founded by patient Kyle Bryant, that increases FA awareness and raises funds to treat and cure FA through research. Under the terms of the grant, CRISPR Therapeutics will develop gene-editing reagents with the potential to address the underlying genetic causes of FA. Dr. Napierala and colleagues will then evaluate the reagents in humanized animal models of FA to demonstrate preclinical proof-of-concept. Upon conclusion of these studies, CRISPR Therapeutics will have the option to advance the compounds into clinical trials.